Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Plans FDA Submissions in May or June for Troponin Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Beckman Coulter today said that it anticipates filing for US clearance on its troponin test during May or June.

In a document filed with the US Securities and Exchange Commission, the Orange County, Calif.-based firm said that it plans to file two separate 510(k) applications with the FDA for the troponin test, one to be run on its Access instruments, the other on its Dxl instruments. Its time estimate is based on the current status of its clinical trial for the test, including site and patient enrolment, and preliminary myocardial infarction incidence rates observed.

Beckman Coulter had previously stated that it anticipated submitting to the FDA for the troponin test in the first half of this year.

The test had run into quality control problems a year ago when the company informed customers of a positive bias in results for its troponin test kits running on its UniCel Dxl immunoassay system.

Beckman Coulter is reportedly in the process of shopping for a buyer in a deal that could fetch $5 billion.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.